Rivastigmine (Exelon) for dementia in patients with Parkinson's disease
Article first published online: 13 OCT 2003
Acta Neurologica Scandinavica
Volume 108, Issue 5, pages 368–373, November 2003
How to Cite
Giladi, N., Shabtai, H., Gurevich, T., Benbunan, B., Anca, M. and Korczyn, A. D. (2003), Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurologica Scandinavica, 108: 368–373. doi: 10.1034/j.1600-0404.2003.00211.x
- Issue published online: 13 OCT 2003
- Article first published online: 13 OCT 2003
- Accepted for publication July 14, 2003
- Parkinson's disease;
- acetylcholinesterase inhibitors;
Objectives – To study the efficacy of cholinesterase inhibitors in the treatment of dementia in patients with Parkinson's disease (PD).
Methods – We treated twenty-eight demented patients with PD openly for 26 weeks with rivastigmine (mean daily dose 7.2 ± 3.3 mg/day). Baseline scores were compared with those at weeks 12, 26 and after 8 weeks of washout.
Results – Twenty patients completed 26 weeks of treatment and eight dropped out because of side effects. The Unified Parkinson's Disease Rating Scale mental subscore improved significantly at week 26 (P < 0.01) while the motor score (part III) did not change. The mean ADAScog total score improved by 7.3 points at week 26 (P < 0.002). The subscores for recognition, word finding, remembering instructions and concentration items of the ADAScog improved significantly as well (P < 0.02, P < 0.05, P < 0.005 and P < 0.003, respectively).
Conclusions – Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function.